<DOC>
	<DOCNO>NCT01253551</DOCNO>
	<brief_summary>The purpose study confirm absence clinically relevant interaction telaprevir raltegravir steady-state.Telaprevir investigated treatment chronic hepatitis C virus infection , raltegravir use treat HIV infection .</brief_summary>
	<brief_title>VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir Raltegravir</brief_title>
	<detailed_description>This open-label , randomize ( order receive treatment session determine chance , like toss coin ) , crossover ( participant receive different intervention sequentially trial ) study healthy participant investigate effect telaprevir 750 mg , every 8 hour , pharmacokinetics ( drug absorb bloodstream , distribute body eliminate body ) raltegravir 400 mg , twice day , vice versa . The study population consist 20 healthy participant . Each individual participant receive two treatment : Treatment A ( telaprevir 750 mg , every 8 hour , alone , Days 1 6 , morning dose Day 7 ) Treatment B ( raltegravir 400 mg , twice day , Days 1 10 telaprevir 750 mg , every 8 hour , Days 5 10 , morning dose raltegravir , morning afternoon dose telaprevir Day 11 ) . Half participant receive first Treatment A Treatment B ; half receive first Treatment B Treatment A . There washout period least 14 day 2 session . The screening period maximum 21 day ; treatment duration approximately 4.5 week , follow-up period 30 31 day . All study medication take food . On Day 7 Treatment A Day 11 Treatment B , 9 blood sample take determination level telaprevir blood . On Days 4 11 Treatment B , 10 blood sample take determination level raltegravir blood . Predose pharmacokinetic sample collect day treatment session . Safety tolerability evaluate throughout trial evaluate result blood urine analysis , vital sign , physical examination , electrocardiogram ( electrical record heart ) , drug alcohol screening , assess participant feeling . In Treatment A , participant receive 2 oral tablet telaprevir 375 mg every 8 hour Days 1 6 , morning dose Day 7 . In Treatment B , participant receive 1 oral tablet 400 mg raltegravir twice day Days 1 10 2 oral tablet 375 mg telaprevir every 8 hour Days 5 10 , morning dose raltegravir , morning afternoon dose telaprevir Day 11 .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Healthy basis physical examination , medical history , vital sign , electrocardiogram clinical laboratory test screen A Body Mass Index 18.0 30.0 kg/m2 , extremes included Women must postmenopausal least 2 year , surgically sterile breastfeed Men must agree use 2 highly effective method birth control donate sperm study 3 month receive last dose study drug Be nonsmoking least 3 month prior selection . Current use prescription medication , regular treatment overthecounter medication ( stop less 7 day prior first intake study medication ) consumption herbal medication dietary supplement , vitamin , grapefruit grapefruit juice , apple juice orange juice within 14 day first intake study medication Consumption 2 unit alcoholic beverage per day 14 unit per week ( 1 unit alcohol equal 1 glass beer , 1 glass wine , 25 mL shoot 40 % spirit ) , consumption alcohol 72 hour study medication intake , consumption average five 240 mL serving coffee caffeinated beverage , eg , tea , cola per day History evidence current use alcohol , barbiturate , amphetamine , recreational narcotic drug use Received investigational drug vaccine use investigational medical device within 3 month 5 half life ( whichever longer ) plan start treatment participate previously study telaprevir .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>VX-950HEP1001</keyword>
	<keyword>hepatitis</keyword>
	<keyword>telaprevir</keyword>
	<keyword>raltegravir</keyword>
	<keyword>crossover</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>VX-950 .</keyword>
</DOC>